Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 1033 Carboplatin 971 Paclitaxel 942 Gemcitabine 799 Cisplatin 757 Docetaxel 698 Bevacizumab 637 Nivolumab 520 Pemetrexed 507 Capecitabine 475 Cyclophosphamide 473 Fluorouracil 425 Dexamethasone 410 Rituximab 391 Oxaliplatin 352 Injections 347 Trastuzumab 313 atezolizumab 312 Cetuximab 291 Leucovorin 290 Irinotecan 271 130-nm albumin-bound paclitaxel 257 Prednisone 251 Ipilimumab 244 Doxorubicin 241 Lenalidomide 231 Fulvestrant 226 fludarabine 219 durvalumab 211 Erlotinib Hydrochloride 196

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Diuretics × Clear all

NCT02215733 2014-08-13

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

1,165,781 enrolled

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡